Bluechiip Limited Raises $2.13m From Investors To Fund North American Sales Push

Bluechiip Limited (ASX: BCT) operates in the biopreservation and sample management laboratory market for harsh environments.

The funds raised will provide direct-to-market sales opportunities in the U.S. where the potential market is over 300 million samples a year.

Recently, it completed installations at two further top-20 pharmaceutical companies in North America.

As early adopters of new technology, Bluechiips Ltd CEO Andrew McLellan said he is confident that there are additional opportunities for its technology across other laboratories within these two large pharma companies.

These are on top of the currently installed and operating Bluechiip systems within another major top 20 global pharma.

The New York State Psychiatric Research Institution based at Columbia University in New York installed a Bluechiip operating system.

Bluechiip has pioneered a workstation platform reader that represents a step change for users.

With an integrated touch-screen and the ability to read multiple box formats of vials the Bluechiip Workstation provides significant productivity and quality improvements.

Mr Mclellan said he he was confident that the successful capital raise positioned Bluechiip well to “transition to a sustainable, cash-flow-positive future sustainable, cash-flow-positive future.”

Articles of Interest